Other MPIP sponsors -- Johnson & Johnson, Bristol-Myers Squibb, Takeda, and Merck -- as well as Novartis and Pfizer have endorsed the 10 recommendations.

The complete list, published in the May issue of Mayo Clinic Proceedings by Maja Zecevic, PhD, MD, of The Lancet, and colleagues, is as follows:

1. Ensure clinical studies and publications address clinically important questions.
2. Make public all results, including negative or unfavorable ones, in a timely fashion, while avoiding redundancy.
3. Improve understanding and disclosure of authors' potential conflicts of interest.
4. Educate authors on how to develop quality manuscripts and meet journal expectations.
5. Improve disclosure of authorship contributions and writing assistance, and continue education on best publication practices to end ghostwriting and guest authorship.
6. Report adverse event data more transparently and in a more clinically meaningful manner.
7. Provide access to more complete protocol information.
8. Transparently report statistical methods used in analysis.
9. Ensure authors can access complete study data, know how to do so, and can attest to this.
10. Support the sharing of prior reviews from other journals.